Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
94.03
-1.40 (-1.47%)
Apr 25, 2025, 12:10 PM EDT - Market open
Glaukos Revenue
In the year 2024, Glaukos had annual revenue of $383.48M with 21.85% growth. Glaukos had revenue of $105.50M in the quarter ending December 31, 2024, with 28.09% growth.
Revenue (ttm)
$383.48M
Revenue Growth
+21.85%
P/S Ratio
13.13
Revenue / Employee
$385,408
Employees
995
Market Cap
5.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GKOS News
- 2 days ago - Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - Business Wire
- 9 days ago - Glaukos Announces the Release of its 2024 Sustainability Report - Business Wire
- 16 days ago - Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30 - Business Wire
- 6 weeks ago - RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution - Business Wire
- 2 months ago - FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery - Benzinga
- 2 months ago - Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™ - Business Wire
- 2 months ago - Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition - Benzinga
- 2 months ago - Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript - Seeking Alpha